CAR-T cell therapy for stubborn lupus kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-phase trial tests a special immune cell therapy (CAR-T) for people with lupus nephritis that has not improved with standard treatments. The therapy uses your own modified cells to target and calm the overactive immune system causing kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lupus nephritis (kidney problems from lupus).
- Previous treatments for lupus nephritis have not worked well.
- You have active kidney inflammation (e.g., protein or blood in your urine).
- You currently take steroids (like prednisone) or antimalarials (like hydroxychloroquine).
- You agree to use effective birth control during the study and for one year after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.